Jerry Wood, MD
Adult Medicine · Livingston, TXNPI 1508866450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations.
Across 103 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$195
- Amgen$183
- AbbVie$176
- Sunovion Pharmaceuticals Inc.$156
- Lilly USA, LLC$119
- Merck$116
- plus $830 from 26 others
What the payments were for
- Food & beverage$1,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $195 |
| Amgen | 10 | $183 |
| AbbVie(2 entities) | 8 | $176 |
| Sunovion Pharmaceuticals Inc. | 12 | $156 |
| Lilly USA, LLC | 8 | $119 |
| Merck | 8 | $116 |
| Johnson & Johnson | 7 | $89 |
| Eisai Inc. | 4 | $85 |
| Dexcom, Inc. | 3 | $57 |
| Mylan Specialty L.p. | 3 | $52 |
| AstraZeneca | 2 | $51 |
| Philips North America LLC | 3 | $47 |
| Bayer | 2 | $41 |
| Exact Sciences | 2 | $41 |
| Pfizer | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Henry Schein, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Novo Nordisk | 2 | $24 |
| Lundbeck LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biogen | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,776 in reported general payments places this provider in the 70th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $77,718 |
| EliquisApixaban | 118 | $72,478 |
| FarxigaDapagliflozin Propanediol | 59 | $40,547 |
| RybelsusSemaglutide | 32 | $34,966 |
| XareltoRivaroxaban | 63 | $32,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $22,479 |
| MounjaroTirzepatide | 20 | $21,860 |
| JardianceEmpagliflozin | 26 | $17,277 |
| JanuviaSitagliptin Phosphate | 18 | $15,572 |
| LinzessLinaclotide | 17 | $11,353 |
| MultaqDronedarone Hcl | 12 | $9,199 |
| EntrestoSacubitril/Valsartan | 19 | $6,826 |
| InvokanaCanagliflozin | 12 | $5,604 |
| MyrbetriqMirabegron | 13 | $5,220 |
| Atorvastatin Calcium | 613 | $4,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $24 | $112,685110 claims |
| PfizerEliquis | $37 | $72,478118 claims |
| AstraZenecaFarxiga | $51 | $40,54759 claims |
| Johnson & JohnsonXarelto, Invokana | $89 | $38,15975 claims |
| GSKTrelegy Ellipta | $195 | $22,47934 claims |
| Lilly USA, LLCMounjaro | $119 | $21,86020 claims |
| Boehringer IngelheimJardiance | $18 | $17,27726 claims |
| MerckJanuvia | $116 | $15,57218 claims |
| AbbVieLinzess, Synthroid | $176 | $12,76056 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $9,19912 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $5,22013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Livingston
- David BuescherLivingston$3K
- Raymond LunaLivingston$1K
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.